Reviewing Century Therapeutics (NASDAQ:IPSC) and Dianthus Therapeutics (NASDAQ:DNTH)

Century Therapeutics (NASDAQ:IPSC) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Century Therapeutics and Dianthus Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1	2	4	0	2.43
Dianthus Therapeutics	1	0	13	2	3.00

Century Therapeutics presently has a consensus target price of $4.75, suggesting a potential upside of 220.95%. Dianthus Therapeutics has a consensus target price of $128.54, suggesting a potential upside of 56.28%. Given Century Therapeutics’ higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Dianthus Therapeutics.

Institutional & Insider Ownership

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Century Therapeutics and Dianthus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Volatility & Risk

Century Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.

Earnings and Valuation

This table compares Century Therapeutics and Dianthus Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	N/A	N/A	-$9.58 million	($0.93)	-1.59
Dianthus Therapeutics	$2.04 million	2,209.46	-$162.34 million	($4.15)	-19.82

Century Therapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.